150 related articles for article (PubMed ID: 24723223)
21. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
[TBL] [Abstract][Full Text] [Related]
22. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
24. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
25. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
26. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
27. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting
Wang Z; Pan L; Yu H; Wang Y
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29592872
[TBL] [Abstract][Full Text] [Related]
28. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
[TBL] [Abstract][Full Text] [Related]
29. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
30. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
[TBL] [Abstract][Full Text] [Related]
31. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
32. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Wang N; Zhang T
Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
[TBL] [Abstract][Full Text] [Related]
34. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K
Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
36. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
37. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
38. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Deng QF; Su B; Zhao YM; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Ge X; Zheng L; Huang M; Wang Y; Bi F
Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
[TBL] [Abstract][Full Text] [Related]
40. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
